Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Neoplasms 10 Venous Thromboembolism 7 Venous Thrombosis 3 Treatment of Venous Thromboembolism in Cancer Patients 3 Pulmonary Embolism 3 Upper Extremity Deep Vein Thrombosis 2 Thrombosis 1 Recurrence 1 Prevention of Venous Thromboembolism 1 Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery 1 Myeloproliferative Disorders 1 Lung Neoplasms 1 Hemorrhage 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

fludarabine phosphate 58 Cyclophosphamide 54 Peripheral Blood Stem Cell Transplantation 49 Mycophenolic Acid 39 Busulfan 38 Tacrolimus 37 Cyclosporine 33 Antilymphocyte Serum 33 Whole-Body Irradiation 32 Filgrastim 28 Methotrexate 27 Radiotherapy 20 Melphalan 18 Cytarabine 17 fludarabine 16 Etoposide 16 Methylprednisolone 14 ruxolitinib 11 sargramostim 9 Flow Cytometry 9 Cyclosporins 9 Cord Blood Stem Cell Transplantation 9 Alemtuzumab 9 thymoglobulin 8 Sirolimus 8 Psychiatric Rehabilitation 8 Granulocyte Colony-Stimulating Factor 8 Azacitidine 8 merphos 7 Decitabine 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Myeloproliferative Disorders × Rivaroxaban × Clear all

NCT04192916 2021-02-21

MPN-DOACs

FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS

Myeloproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon ⚡